RIFADIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rifadin, and when can generic versions of Rifadin launch?
Rifadin is a drug marketed by Sanofi Aventis Us and is included in three NDAs.
The generic ingredient in RIFADIN is rifampin. There are nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the rifampin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rifadin
A generic version of RIFADIN was approved as rifampin by EPIC PHARMA LLC on May 28th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RIFADIN?
- What are the global sales for RIFADIN?
- What is Average Wholesale Price for RIFADIN?
Summary for RIFADIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 47 |
| Clinical Trials: | 35 |
| Patent Applications: | 6,837 |
| Drug Prices: | Drug price information for RIFADIN |
| What excipients (inactive ingredients) are in RIFADIN? | RIFADIN excipients list |
| DailyMed Link: | RIFADIN at DailyMed |
Recent Clinical Trials for RIFADIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| TASK Applied Science | Phase 2 |
| GlaxoSmithKline | Phase 2 |
| University of Cape Town | Phase 3 |
Pharmacology for RIFADIN
| Drug Class | Rifamycin Antibacterial |
US Patents and Regulatory Information for RIFADIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | RIFADIN | rifampin | CAPSULE;ORAL | 062303-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | RIFADIN | rifampin | CAPSULE;ORAL | 050420-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | RIFADIN | rifampin | INJECTABLE;INJECTION | 050627-001 | May 25, 1989 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
